Using Docefrez for Non-Small Cell Lung Cancer (NSCLC)Lung cancer occurs when cancer cells begin to grow in the tissues of the lung. There are two main types of lung cancer: small cell lung cancer and non-small cell lung cancer. Non-small cell lung cancer is more common than small cell lung cancer, and usually spreads more slowly.
After a diagnosis of lung cancer has been made, tests are done to find out if cancer cells have spread within the lungs or to other parts of the body. Lung cancer that has spread to nearby tissue or to lymph nodes is considered locally advanced lung cancer. Locally advanced lung cancer is also called stage III lung cancer.
Metastatic lung cancer is lung cancer that has spread to other organs of the body, such as the brain or the other lung. Metastatic lung cancer is also called stage IV cancer (see Non-Small Cell Lung Cancer Stages for more information on the stages of lung cancer).
Docefrez is approved to treat locally advanced or metastatic NSCLC. It is meant for use after platinum-based chemotherapy has been tried but failed. Platinum-based chemotherapy medications include cisplatin, carboplatin, and oxaliplatin (Eloxatin®).
Using Docefrez for Prostate CancerThe prostate is a small gland that secretes much of the liquid portion of semen, the milky fluid that transports sperm through the penis during ejaculation. Prostate cancer occurs when cancer cells begin to grow in the prostate gland. The growing cells form an abnormal mass of tissue called a tumor.
Prostate cancer is generally slow-growing compared with most other types of cancer. Cell changes may begin 10, 20, or 30 years before a tumor is big enough to cause symptoms. Eventually, however, the prostate cancer becomes more advanced and can spread to the surrounding tissue or other areas of the body.
Treatment for prostate cancer can vary, depending on a number of things, such as whether the cancer has spread to other areas of the body (called metastatic prostate cancer) and a man's general overall health. One type of treatment for prostate cancer involves hormone therapy (see Prostate Cancer Treatment for information about other types of treatment available for prostate cancer).
Prostate cancer hormone therapy includes using hormones or surgery to keep cancer cells from obtaining the male hormones (androgens) they need to grow. For example, a group of drugs known as luteinizing hormone-releasing hormone (LH-RH) agonists prevent the testicles from making testosterone. Anti-androgens, another group of hormone treatment medicines, block the action of male hormones (see Prostate Cancer Hormone Therapy for more information).
Surgery can also be used to remove the testicles, which are the body's primary source of testosterone (the adrenal gland also makes some testosterone).
Hormone refractory prostate cancer occurs when hormone therapy no longer stops the growth of cancer cells. Prostate cancer can become hormone refractory months or years after hormone therapy is initiated. Hormone refractory prostate cancer is also called androgen independent prostate cancer.
Docefrez is approved to treat hormone refractory metastatic prostate cancer. It is approved for use in combination with prednisone, a corticosteroid medication.